<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202787</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-04-02</org_study_id>
    <secondary_id>eudract-number: 2004-001700-12</secondary_id>
    <nct_id>NCT00202787</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer</brief_title>
  <official_title>Open-label, Phase II, Randomised, Pilot Study to Evaluate the Safety and Efficacy of Combination Therapy With Cetuximab and FOLFOX4 or FOLFOX4 Alone in Patients Colorectal Cancer and Initially Non-resectable</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine confirmed objective response rate to combination
      therapy with cetuximab and FOLFOX4 or FOLFOX4 alone in patients with CRC and non-resectable
      hepatic metastases
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine confirmed objective response rate</measure>
    <time_frame>2005-2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine safety of combination, surgical resectability and R0 resections, clinical benefit, time to disease progression, time to onset of response, duration of response, time to treatment failure, overall survival time</measure>
    <time_frame>2005-2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of polymorphisms of the intron 1 of the EGFR gene, TS, XRCC1, XPD, serum levels of EGFR and ATP7A and ATP7B, nÂº of copies of EGFR gene, the levels of PTEN, EGFR, AKT y MAPK proteins, and mutations at EGFR, PI3KCA, K-RAS y B-RAF genes</measure>
    <time_frame>2005-2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX-4+cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX-4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX-4+cetuximab</intervention_name>
    <description>Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);
FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX-4</intervention_name>
    <description>FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Men and women &lt; 75 years

          -  Histologically confirmed diagnosis of CRC

          -  Metastatic colorectal carcinoma with exclusive non-resectable hepatic metastases, due
             to fulfillment of one of the following criteria:

               1. Number of hepatic metastases &gt; or= 4;

               2. Size of one or more hepatic metastases &gt; 5 cm diameter;

               3. Vascular involvement and/or poor site that prevent complete resection of hepatic
                  disease and/or require resection with the remaining liver mass less than 25-30%
                  of functional liver.

          -  Presence of at least one lesion detectable by two-dimensional measurement.

          -  Karnofsky functional status &gt;or=70% at the time of enrollment in study

          -  Life expectancy greater than 3 months.

          -  Patients must not have received chemotherapy for advanced/metastatic disease.

          -  Patients with the following characteristics will be enrolled:

               1. Recurrence after adjuvant treatment with 5-fluorouracil/folinic acid or
                  capecitabine +/- radiotherapy with disease-free period &gt; 6 months following
                  conclusion of treatment.

               2. Recurrence after surgical and/or radiotherapy treatment without adjuvant systemic
                  treatment.

               3. De novo diagnosis of disease.

          -  Proper liver function, defined by aspartate aminotransferase (AST/SGOT) and alanine
             aminotransferase (ALT/SGPT) &lt; or = 2.5 x ULN (&lt; or = 5 x ULN if there are hepatic
             metastases) and total bilirubin count &lt; 1.5 x ULN.

          -  Proper kidney function, defined as serum creatinine &lt; 1.5 x ULN.

          -  Proper hematological function, defined as neutrophil count &gt; or = 1.5 x 109/l ,
             platelets &gt; or = 100 X 109/l and hemoglobin &gt; or = 9 g/dl.

          -  Effective birth control method for men as well as women if there is possibility of
             pregnancy

        Exclusion Criteria:

          -  Documented or suspected cerebral and/or leptomeningeal metastases.

          -  Metastasis in any other non-hepatic site, including extrahepatic lymph node
             metastases.

          -  Surgery (excluding biopsy for diagnosis) and/or radiotherapy within 4 weeks prior to
             enrollment in the study.

          -  Participation in another clinical trial with medication in the past 30 days.

          -  Chronic, concomitant administration of systemic immunotherapy, chemotherapy, hormone
             therapy or any other investigational drug.

          -  Prior malignant tumour in past 5 years, except history of basal cell skin carcinoma or
             pre-invasive cervical carcinoma.

          -  Any investigational drug during the 4 weeks prior to enrolment.

          -  Prior administration of monoclonal antibodies, EGFR signal transduction inhibitors or
             EGFR-targeted treatment.

          -  Prior participation in study in which treatment with cetuximab can be assigned
             (whether or not treatment with cetuximab is received)

          -  Acute or subacute intestinal occlusion or history of inflammatory intestinal disease.

          -  Evidence of grade 3 or 4 allergic reaction to any of the treatment components.

          -  Clinically relevant peripheral neuropathy.

          -  Clinically relevant myocardial disease or history of myocardial infarction in the past
             12 months.

          -  Known abuse of alcohol / drugs, Legal incapacity or limited legal capacity.

          -  Any medical or psychological disorder which, in the opinion of the investigator, does
             not allow the patient to conclude the study or sign the informed consent.

          -  Pregnant or nursing woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Abad</last_name>
    <role>Study Chair</role>
    <affiliation>Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>cetuximab</keyword>
  <keyword>FOLFOX4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

